AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 122 min read$MIRM

Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 results for LIVMARLI in treating cholestatic pruritus in rare liver diseases. The study met its primary endpoint, showing significant itch reduction and bile acid decrease. The company plans a 2027 FDA submission. Shares rose 5.73% on Friday.

Original reporting
rttnews.com
Published Oct 12, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study — source image
Source · rttnews.com
Decision brief

The 30-second read

$MIRMBullishHigh
01

Why it matters

The Phase 3 data provides a clear efficacy signal, supporting a supplemental NDA filing in H1 2027, which could unlock a larger market.

02

Market read

Positive trial data is a catalyst for biotech stocks; MIRM shares already rose pre‑market, indicating immediate market reaction.

03

What to watch

Potential competition from other pruritus treatments and the need for FDA approval timeline.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Mirum Pharmaceuticals (MIRM) is a biotech focused on rare cholestatic liver diseases. LIVMARLI is already approved for Alagille syndrome and PFIC.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum Pharmaceuticals reported positive Phase 3 trial results for LIVMARLI, showing statistically significant improvement in itch severity and bile acid reduction.

Expected impact

upward pressure as investors price in the successful trial and upcoming NDA filing.

Evidence & confidence

Phase 3 success is material for a biotech and often triggers a rally, especially with pre‑market price already up.

Market effects

Sector

Strengthens outlook for rare‑disease biotech sector and may boost peer valuations.

Regional

US biotech market could see modest gains on the news.

Global

Limited to investors focused on rare‑disease therapeutics.

Counterpoint

What could challenge this read

If regulatory review raises concerns, the rally could be short‑lived.

Key entities

  • company
    Mirum Pharmaceuticals

    Biotech developer of LIVMARLI.

  • drug
    LIVMARLI (maralixibat)

    Therapeutic for cholestatic pruritus.

Read at source← All news

StoryMirum reports Phase 3 EXPAND trial meets primary and secondary endpoints for LIVMARLI

Also covered by

1 outlet

Related articles

OCT 12
$MIRMMedAI 8/10

Mirum tees up Livmarli label expansion on Phase III liver disease study success

Mirum Pharmaceuticals' Livmarli showed success in a Phase III trial for treating itch in rare liver diseases, meeting all endpoints. The drug reduced itch scores and blood bile acid levels significantly. Mirum plans to submit an sNDA in 2027, potentially expanding Livmarli's label. Analysts project $876m in sales by 2032. Livmarli is currently FDA-approved for two rare liver conditions.

finance.yahoo.com6 min
OCT 12
$MIRMHighAI 8/10

Baird reiterates Mirum Pharmaceuticals stock rating on trial success

Baird reiterated an Outperform rating and $130 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for maralixibat. The study met primary and secondary endpoints, with 50% of patients having biliary atresia. The company reported 44% revenue growth over the last year and is valued at $5.41 billion. Analysts revised earnings upwards, with price targets ranging from $118 to $195.

investing.com2 min
OCT 12
$MIRMHighAI 9/10

Mirum’s maralixibat meets primary endpoint in liver disease trial

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 trial results for maralixibat in treating cholestatic pruritus in rare liver diseases. The drug met its primary endpoint, showing significant improvement in itch severity and serum bile acids reduction compared to placebo. Mirum plans to submit a supplemental New Drug Application in the U.S. in early 2027.

investing.com2 min